Lloyd Payne F2G's Chief Scientific Officer.

Lloyd was previously a senior scientist at Millennium Pharmaceuticals where he was responsible for the leadership of multidisciplinary drug discovery project teams based in the UK and the US. Lloyd provided direction for a number of medicinal chemistry programs from early hit validation to late stage lead optimisation and has led several successful projects focused on the development of therapies for inflammatory disorders and cancer. One such program has since delivered a novel, orally administered small molecule therapeutic into the clinic.

Lloyd has also held senior scientific and management positions within Cambridge Discovery Chemistry Ltd and NCE Discovery Ltd where he was responsible for a number of collaborative medicinal chemistry projects working with organisations across Europe, Japan and the U.S.

Back